ALS and Airway Clearance (ALSAC) Therapy

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 25, 2012

Primary Completion Date

September 21, 2016

Study Completion Date

September 17, 2017

Conditions
Amyotrophic Lateral SclerosisRespiratory Muscle Weakness
Interventions
DEVICE

High Frequency Chest Wall Oscillation

The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.

DEVICE

Mechanical insufflation/exsufflation

A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.

Trial Locations (1)

78229

University of Texas Health San Antonio, San Antonio

All Listed Sponsors
collaborator

ALS Association

OTHER

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT04947436 - ALS and Airway Clearance (ALSAC) Therapy | Biotech Hunter | Biotech Hunter